NCT01673425

Evaluating Immune Response to Seasonal FluMist in Healthy Adults

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: National Center for Occupational Health and Infection Control · Federal
• Sex: All
• Age: 20 Years – 49 Years
• Healthy volunteers: Accepted

Summary

The Live-Attenuated Influenza Vaccine (LAIV), also known as FluMist, has been shown to be effective in children but less effective in adults. Our hypothesis is that this relative failure is due to adults having enough anti-flu IgA antibody in nasal secretions to neutralize the weakened vaccine virus.

Detailed description

This is a VA-based study to evaluate serum and nasal wash antibody responses to seasonal LAIV of healthy Veterans and VA employees between the ages of 20 and 49 years old. Specific Aims 1. The primary aim of the study is to evaluate whether people with high mucosal IgA antibodies against flu have a lower immune response to the seasonal LAIV. 2. The secondary objective is to determine whether the nasal wash viral neutralization data predicts LAIV immunization failures.

Conditions

• Influenza

Interventions

Type	Name	Description
DRUG	Live Attenuated Influenza Vaccine	All participants will be given FluMist.

Timeline

• Start date: 2012-09-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2012-08-28
• Last updated: 2021-01-27
• Results posted: 2014-09-04

Locations

1 site across 1 country: United States